Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses

Guido Grassi, Anna Pisano, Davide Bolignano, Gino Seravalle, Graziella D'Arrigo, Fosca Quarti-Trevano, Francesca Mallamaci, Carmine Zoccali, Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

Muscle sympathetic nerve activity (MSNA) has shown that sympathetic activation may occur in essential hypertension (EHT). However, the small sample size of the studies, the heterogeneity of the patients examined, and the presence of confounders represented major weaknesses not allowing to draw definite conclusions. Among the 432 studies identified providing information in EHT on MSNA, 63 were eligible (1216 patients) and meta-analyzed grouping them on the basis of clinically relevant questions: (1) Is MSNA increased in hypertension of mild/moderate-to-severe degree? (2) Does sympathetic activation occur in borderline, white-coat, and masked EHT? (3) Is MSNA related to clinic and ambulatory blood pressure and target organ damage? (4) Are heart rate and venous plasma norepinephrine valuable surrogate markers of MSNA in clinical practice? The results show that MSNA was significantly greater (1.5×; P<0.001) in mild-to-moderate and severe EHT as compared with normotensive controls and that this was the case also in borderline, white-coat, and masked hypertension as well. Interestingly, MSNA was significantly greater in both untreated and treated hypertension (P<0.001 for both), related to clinic and ambulatory blood pressure (r=0.67 and r=0.83; P<0.001 for both), inversely related to heart rate (r=-0.38; P<0.001) and directly to venous plasma norepinephrine (r=0.28; P<0.001) and left ventricular mass index (r=0.27; P<0.001). Thus, EHT is a condition characterized by a sustained sympathetic overdrive, whose magnitude is proportional to its clinical severity. This is more clearly manifest when MSNA rather than indirect markers of adrenergic drive, such as heart rate and plasma norepinephrine, are used.

Original languageEnglish
Pages (from-to)483-491
Number of pages9
JournalHypertension (Dallas, Tex. : 1979)
Volume72
Issue number2
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Meta-Analysis
Muscles
Masked Hypertension
Norepinephrine
Heart Rate
White Coat Hypertension
Blood Pressure
Hypertension
Essential Hypertension
Adrenergic Agents
Sample Size
Biomarkers

Cite this

Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates : Systematic Reviews and Meta-Analyses. / Grassi, Guido; Pisano, Anna; Bolignano, Davide; Seravalle, Gino; D'Arrigo, Graziella; Quarti-Trevano, Fosca; Mallamaci, Francesca; Zoccali, Carmine; Mancia, Giuseppe.

In: Hypertension (Dallas, Tex. : 1979), Vol. 72, No. 2, 08.2018, p. 483-491.

Research output: Contribution to journalArticle

Grassi, G, Pisano, A, Bolignano, D, Seravalle, G, D'Arrigo, G, Quarti-Trevano, F, Mallamaci, F, Zoccali, C & Mancia, G 2018, 'Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses', Hypertension (Dallas, Tex. : 1979), vol. 72, no. 2, pp. 483-491. https://doi.org/10.1161/HYPERTENSIONAHA.118.11038
Grassi, Guido ; Pisano, Anna ; Bolignano, Davide ; Seravalle, Gino ; D'Arrigo, Graziella ; Quarti-Trevano, Fosca ; Mallamaci, Francesca ; Zoccali, Carmine ; Mancia, Giuseppe. / Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates : Systematic Reviews and Meta-Analyses. In: Hypertension (Dallas, Tex. : 1979). 2018 ; Vol. 72, No. 2. pp. 483-491.
@article{cd55cf0a818140de9e25012ef48684e8,
title = "Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses",
abstract = "Muscle sympathetic nerve activity (MSNA) has shown that sympathetic activation may occur in essential hypertension (EHT). However, the small sample size of the studies, the heterogeneity of the patients examined, and the presence of confounders represented major weaknesses not allowing to draw definite conclusions. Among the 432 studies identified providing information in EHT on MSNA, 63 were eligible (1216 patients) and meta-analyzed grouping them on the basis of clinically relevant questions: (1) Is MSNA increased in hypertension of mild/moderate-to-severe degree? (2) Does sympathetic activation occur in borderline, white-coat, and masked EHT? (3) Is MSNA related to clinic and ambulatory blood pressure and target organ damage? (4) Are heart rate and venous plasma norepinephrine valuable surrogate markers of MSNA in clinical practice? The results show that MSNA was significantly greater (1.5×; P<0.001) in mild-to-moderate and severe EHT as compared with normotensive controls and that this was the case also in borderline, white-coat, and masked hypertension as well. Interestingly, MSNA was significantly greater in both untreated and treated hypertension (P<0.001 for both), related to clinic and ambulatory blood pressure (r=0.67 and r=0.83; P<0.001 for both), inversely related to heart rate (r=-0.38; P<0.001) and directly to venous plasma norepinephrine (r=0.28; P<0.001) and left ventricular mass index (r=0.27; P<0.001). Thus, EHT is a condition characterized by a sustained sympathetic overdrive, whose magnitude is proportional to its clinical severity. This is more clearly manifest when MSNA rather than indirect markers of adrenergic drive, such as heart rate and plasma norepinephrine, are used.",
author = "Guido Grassi and Anna Pisano and Davide Bolignano and Gino Seravalle and Graziella D'Arrigo and Fosca Quarti-Trevano and Francesca Mallamaci and Carmine Zoccali and Giuseppe Mancia",
note = "{\circledC} 2018 American Heart Association, Inc.",
year = "2018",
month = "8",
doi = "10.1161/HYPERTENSIONAHA.118.11038",
language = "English",
volume = "72",
pages = "483--491",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates

T2 - Systematic Reviews and Meta-Analyses

AU - Grassi, Guido

AU - Pisano, Anna

AU - Bolignano, Davide

AU - Seravalle, Gino

AU - D'Arrigo, Graziella

AU - Quarti-Trevano, Fosca

AU - Mallamaci, Francesca

AU - Zoccali, Carmine

AU - Mancia, Giuseppe

N1 - © 2018 American Heart Association, Inc.

PY - 2018/8

Y1 - 2018/8

N2 - Muscle sympathetic nerve activity (MSNA) has shown that sympathetic activation may occur in essential hypertension (EHT). However, the small sample size of the studies, the heterogeneity of the patients examined, and the presence of confounders represented major weaknesses not allowing to draw definite conclusions. Among the 432 studies identified providing information in EHT on MSNA, 63 were eligible (1216 patients) and meta-analyzed grouping them on the basis of clinically relevant questions: (1) Is MSNA increased in hypertension of mild/moderate-to-severe degree? (2) Does sympathetic activation occur in borderline, white-coat, and masked EHT? (3) Is MSNA related to clinic and ambulatory blood pressure and target organ damage? (4) Are heart rate and venous plasma norepinephrine valuable surrogate markers of MSNA in clinical practice? The results show that MSNA was significantly greater (1.5×; P<0.001) in mild-to-moderate and severe EHT as compared with normotensive controls and that this was the case also in borderline, white-coat, and masked hypertension as well. Interestingly, MSNA was significantly greater in both untreated and treated hypertension (P<0.001 for both), related to clinic and ambulatory blood pressure (r=0.67 and r=0.83; P<0.001 for both), inversely related to heart rate (r=-0.38; P<0.001) and directly to venous plasma norepinephrine (r=0.28; P<0.001) and left ventricular mass index (r=0.27; P<0.001). Thus, EHT is a condition characterized by a sustained sympathetic overdrive, whose magnitude is proportional to its clinical severity. This is more clearly manifest when MSNA rather than indirect markers of adrenergic drive, such as heart rate and plasma norepinephrine, are used.

AB - Muscle sympathetic nerve activity (MSNA) has shown that sympathetic activation may occur in essential hypertension (EHT). However, the small sample size of the studies, the heterogeneity of the patients examined, and the presence of confounders represented major weaknesses not allowing to draw definite conclusions. Among the 432 studies identified providing information in EHT on MSNA, 63 were eligible (1216 patients) and meta-analyzed grouping them on the basis of clinically relevant questions: (1) Is MSNA increased in hypertension of mild/moderate-to-severe degree? (2) Does sympathetic activation occur in borderline, white-coat, and masked EHT? (3) Is MSNA related to clinic and ambulatory blood pressure and target organ damage? (4) Are heart rate and venous plasma norepinephrine valuable surrogate markers of MSNA in clinical practice? The results show that MSNA was significantly greater (1.5×; P<0.001) in mild-to-moderate and severe EHT as compared with normotensive controls and that this was the case also in borderline, white-coat, and masked hypertension as well. Interestingly, MSNA was significantly greater in both untreated and treated hypertension (P<0.001 for both), related to clinic and ambulatory blood pressure (r=0.67 and r=0.83; P<0.001 for both), inversely related to heart rate (r=-0.38; P<0.001) and directly to venous plasma norepinephrine (r=0.28; P<0.001) and left ventricular mass index (r=0.27; P<0.001). Thus, EHT is a condition characterized by a sustained sympathetic overdrive, whose magnitude is proportional to its clinical severity. This is more clearly manifest when MSNA rather than indirect markers of adrenergic drive, such as heart rate and plasma norepinephrine, are used.

U2 - 10.1161/HYPERTENSIONAHA.118.11038

DO - 10.1161/HYPERTENSIONAHA.118.11038

M3 - Article

C2 - 29915014

VL - 72

SP - 483

EP - 491

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -